GATC Biotech Orders Europe’s First HiSeq 2000 for Commercial Use
News Jan 22, 2010
GATC Biotech has announced the purchase of Illumina’s new HiSeq 2000 sequencing platform, which has officially been launched last week. This latest acquisition will further strengthen GATC Biotech’s current fleet of three GA IIx.
Initially, the company will employ the HiSeq 2000 to human genome sequencing projects from its customers in the pharmaceutical and medical research field. It will also make the system’s high data output available to the industrial and academic research community interested in the high throughput sequencing of larger eukaryotic genomes.
“Illumina’s HiSeq 2000 with the estimated output of 200 GB per run allows us to virtually sequence 60 human genomes at 1x coverage in a week. Being an Illumina CSPro certified service provider we are confident to have the system quickly installed and geared up for production,” says Peter Pohl, CEO of GATC Biotech.
The HiSeq 2000 sequencing system had just been launched by llumina Inc. on the occasion of the J.P. Morgan Healthcare Conference last week in San Diego.
Computer scientists at Carnegie Mellon University say neural networks and supervised machine learning techniques can efficiently characterize cells that have been studied using single cell RNA-sequencing (scRNA-seq). This finding could help researchers identify new cell subtypes and differentiate between healthy and diseased cells.